olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.